Aura Biosciences (AURA) Stock Overview
A clinical-stage biotechnology company, develops precision therapies to treat solid tumors. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
AURA Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Aura Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.13 |
| 52 Week High | US$11.29 |
| 52 Week Low | US$4.35 |
| Beta | 0.45 |
| 1 Month Change | -0.33% |
| 3 Month Change | -9.05% |
| 1 Year Change | -39.61% |
| 3 Year Change | -49.09% |
| 5 Year Change | n/a |
| Change since IPO | -58.58% |
Recent News & Updates
Is Aura Biosciences (NASDAQ:AURA) In A Good Position To Deliver On Growth Plans?
May 03
We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth
Jan 11Recent updates
Is Aura Biosciences (NASDAQ:AURA) In A Good Position To Deliver On Growth Plans?
May 03We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth
Jan 11Aura Biosciences: Highly Derisked Late-Stage Eye Cancer Company
Sep 17We're Hopeful That Aura Biosciences (NASDAQ:AURA) Will Use Its Cash Wisely
Sep 11We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth
Oct 03Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth
Mar 28We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth
Oct 01Aura gains as JMP starts with Bullish view citing treatment platform
Jul 19Aura Biosciences' AU-011 gets FDA fast-track status for bladder cancer
Jun 30Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth
Apr 10Shareholder Returns
| AURA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 4.6% | 2.2% | 0.5% |
| 1Y | -39.6% | 5.5% | 19.8% |
Return vs Industry: AURA underperformed the US Biotechs industry which returned 3.4% over the past year.
Return vs Market: AURA underperformed the US Market which returned 19% over the past year.
Price Volatility
| AURA volatility | |
|---|---|
| AURA Average Weekly Movement | 6.8% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AURA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: AURA's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 108 | Eli de los Pinos | www.aurabiosciences.com |
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company’s proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer.
Aura Biosciences, Inc. Fundamentals Summary
| AURA fundamental statistics | |
|---|---|
| Market cap | US$377.69m |
| Earnings (TTM) | -US$101.38m |
| Revenue (TTM) | n/a |
Is AURA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AURA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$101.38m |
| Earnings | -US$101.38m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.63 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did AURA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/31 22:29 |
| End of Day Share Price | 2025/10/31 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Aura Biosciences, Inc. is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jonathan Wolleben | Citizens JMP Securities, LLC |
| Liisa Bayko | Evercore ISI |
| Edward White | H.C. Wainwright & Co. |